As of Oct 27
| -2.68 / -2.06%|
The 20 analysts offering 12-month price forecasts for Intercept Pharmaceuticals Inc have a median target of 202.50, with a high estimate of 350.00 and a low estimate of 60.00. The median estimate represents a +58.82% increase from the last price of 127.50.
The current consensus among 21 polled investment analysts is to Buy stock in Intercept Pharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.